
    
      Relapse rates after chemotherapy for relapsed, refractory or transformed Non-Hodgkin's
      lymphoma (NHL)remain very high. NHL is a radiosensitive tumor. We hypothesize that targeted
      radioimmunotherapy combined with high-dose chemotherapy may increase response and survival
      rates in a safe and reliable manner.
    
  